The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2019 | Minor-clone mutations in CLL patients entering first-line treatment
Jitka Malčíková, PhD, Masaryk University, Brno, Czech Republic, discusses her poster presentation on minor-clone TP53 mutations in chronic lymphocytic leukemia (CLL) patients entering first-line treatment including the clonal evolution and clinical impact of these mutations. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
